Clinical trialObsUnknown
Venous Thromboembolism in Primary Pancreatic Tumour Resection
Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection; a Prospective Observational Study
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 1 September 2023
- Expected end
- 1 October 2024
- Enrollment
- 64 participants
- Sites
- 1
- Primary outcomes
- Neutrophil to lymphocyte ratio-VTE; von Willebrand factor-VTE; Factors VIII and XI-VTE; D-dimers-VTE; Fibrinogen-VTE
- Sponsor
- Other
- Results posted
- No
- Last update
- 28 November 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will evaluate the development of venous thromboembolism (VTE) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.
Detailed description public domain (ClinicalTrials.gov)
Cancer associated thrombosis (CAT) is the second cause of death, in oncologic patients after tumour progression itself. Patients suffering from malignancies are at increased risk for both venous (4-20%) and arterial (2-5%) thrombotic events. Moreover, cancer is one of the most important acquired risk factors for the development of venous thromboembolism (VTE). Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy, with a reported incidence of VTE (8-18%), followed by renal and ovarian cancer (VTE 5.6%). Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state. Aims * To evaluate the predictive value of preoperatively or early postoperatively obtained NLR, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkers/parameters, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection * To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection * To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients' baseline characteristics